KLK3 and prostate cancer: Since its identification, various retrospective and prospective studies have assessed the usefulness of free/total (F/T) PSA ratio (cut-off points of 0.1–0.2) for differentiating between benign conditions and prostate cancer, especially in “gray-zone” patients who have PSA levels of 4–10 ng/ml [2–4].